All In Biotech

NDA 018655 · Pfizer

Norpace Cr

Disopyramide Phosphate · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: May 17, 2000 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Jul 20, 1982

Approved uses

3

Original approval plus efficacy supplements

Registered trials

5

2 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 3, 1991 Supplement 26 · Efficacy
  • Jun 19, 1985 Supplement 8 · Efficacy
  • Jul 20, 1982 Original approval · Type 3 - New Dosage Form
2 products under this application
  • NORPACE CR · DISOPYRAMIDE PHOSPHATE EQ 100MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
  • NORPACE CR · DISOPYRAMIDE PHOSPHATE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Disopyramide" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Norpace Cr (Disopyramide Phosphate)

2024 spending

$1.1M

Beneficiaries

408

1,640 claims

Per beneficiary

$2,757

$4.61 per unit

View as table
YearSpending
2020$1,573,710
2021$159,720
2022$671,757
2023$812,958
2024$1,124,882

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 211 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.